Key Terms & Concepts — UPSC Mains
Biosimilars
"Near-identical copies of approved biologic medicines, comparable in quality, safety, and efficacy to the original"
Biosimilars are biological medicines that are highly similar to an already approved biologic medicine (the reference product). Unlike chemical generics, which are exact molecular copies, biosimilars are produced by living organisms and cannot be perfectly replicated — they are 'similar' but not identical. Biosimilars must demonstrate through rigorous analytical, preclinical, and clinical studies that they have no clinically meaningful differences from the reference product.
Important for GS3 Science & Technology and Economy answers. The Biopharma SHAKTI initiative (Budget 2026-27, Rs 10,000 crore) makes this a high-priority current affairs topic. Understanding the biologics-biosimilars distinction is key for health policy and pharma industry questions.
- 1 Biologics: complex molecules derived from living cells (monoclonal antibodies, vaccines, insulin)
- 2 Biosimilars: similar versions of approved biologics, not exact copies
- 3 India has 95+ approved biosimilars domestically
- 4 India holds only ~3.2% of the global biosimilars market (2025)
- 5 Global biologics market: $500+ billion (expected $800+ billion by 2030)
- 6 Regulated by CDSCO under the Drugs and Cosmetics Act, 1940
- 7 Indian biosimilar leaders: Biocon, Dr Reddy's, Cipla, Zydus
- 8 Key diseases treated: cancer, diabetes, autoimmune disorders, rare diseases
While India supplies 20% of global generic medicines, it holds only 3.2% of the biosimilars market — Biopharma SHAKTI aims to bridge this gap with 3 new NIPERs and 1,000+ clinical trial sites.